Four p27^Kip1 inhibitors and calculated IC₅₀ values that passed all primary and secondary screens.

<p>The activity data for individual compounds were fit into sigmoidal dose-response curves (n = 3 per compound, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091173#pone-0091173-g003" target="_blank">Fig. 3C–F</a>) to derive IC₅₀ values.</p

Secondary screening of primary hits reveals four true <i>p27^Kip1</i> inhibitors.

<p>A. Workflow of the secondary screening procedures. B. Remaining hits after each step of the secondary screen. C–F. Dose-dependent luciferase inhibition (black) and alamar blue inhibition (blue) of each compound (n = 3, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0091173#pone-0091173-t001" target="_blank">Table 1</a> lists the calculated IC₅₀’s). Curves were fitted by a sigmoidal dose-response curve. G–J. Luciferase levels (normalized to DMSO) over 3 doses of each compound showing no effect on SV-40 driven luciferase (n = 3). Green line represents no change from vehicle DMSO to A2CE. K–N. Dose-dependent decrease in endogenous p27^Kip1 mRNA of each compound normalized to that in DMSO control (RT-qPCR) in HeLa cells (n = 3). Mean ± S.E.M., * p<0.05 (One way ANOVA, followed by bonferroni for means comparison).</p

Alsterpaullone, 2-Cyanoethyl inhibits <i>p27^Kip1</i> transcription from diverse cellular origins, and reduces p27^Kip1 protein levels.

<p>A. Immunoblot of p27^Kip1 and β-actin with indicated concentration of A2CE in HeLa cells. B. Relative intensity of p27^Kip1 normalized to β-actin by densitometry (n = 3) with indicated concentrations of A2CE. C. Fold changes of endogenous p27^Kip1 mRNA (normalized to 18s) in HEK cells treated with indicated concentrations of A2CE normalized to DMSO (n = 3). D. Alamar blue cell viability assay in HEK cells treated with indicated concentrations of A2CE. E. Fold changes of endogenous p27^Kip1 mRNA (normalized to 18s) in 3T3 cells treated with indicated concentrations of A2CE normalized to DMSO (n = 3). F. Alamar blue cell viability assay in 3T3 cells treated with indicated concentrations of A2CE G. Fold changes of endogenous p27^Kip1 mRNA (normalized to 18s) in cochlear explants treated with indicated concentrations of A2CE normalized to DMSO (n = 3). H. Alamar blue cell viability assay in cochlear explants treated with indicated concentrations of A2CE. Mean ± S.E.M., * p<0.05 (One way ANOVA, followed by bonferroni for means comparison).</p

Primary screening for inhibition of p27^Kip1-luciferase.

<p>A. Percentage of luciferase inhibition by each compound screened (12 μM), compared to positive control cycloheximide (green), and negative control DMSO (red). Arbitrary threshold was set at 50% luciferase inhibition (yellow line). Compounds which “passed” (blue) and “failed” (black) are shown. B. Percentage of alamar blue inhibition by each compound screened (12 μM) compared to positive control cyclohexamide (green), and negative control DMSO (red). Arbitrary threshold was set at 30% alamar blue inhibition (yellow line). Compounds which inhibited alamar blue more than 30% “failed” (blue), and less than 30% “passed” (black).</p

A High-Throughput Screen Reveals New Small-Molecule Activators and Inhibitors of Pantothenate Kinases

Pantothenate kinase (PanK) is a regulatory enzyme that controls coenzyme A (CoA) biosynthesis. The association of PanK with neurodegeneration and diabetes suggests that chemical modifiers of PanK activity may be useful therapeutics. We performed a high throughput screen of >520000 compounds from the St. Jude compound library and identified new potent PanK inhibitors and activators with chemically tractable scaffolds. The HTS identified PanK inhibitors exemplified by the detailed characterization of a tricyclic compound (<b>7</b>) and a preliminary SAR. Biophysical studies reveal that the PanK inhibitor acts by binding to the ATP–enzyme complex